NCT03100799 is a NA clinical trial of Arthroscopy in Osteoarthritis, Knee, sponsored by Unity Biotechnology, Inc..

Who is sponsoring NCT03100799?

NCT03100799 is sponsored by Unity Biotechnology, Inc..

What drugs are being tested in NCT03100799?

Interventions in NCT03100799: Arthroscopy, Arthrocentesis, MRI.

What condition does NCT03100799 study?

NCT03100799 studies Osteoarthritis, Knee.

Is NCT03100799 still recruiting?

NCT03100799 is currently completed. Last updated 1 August 2017.

Last reviewed 2017-08-01 · How we verify

NCT03100799

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Exploratory Clinical Study to Investigate Biomarkers of Senescence in Patients With Osteoarthritis of the Knee

Completed NA Last updated 1 August 2017

What this trial tests

NA trial testing Arthroscopy in Osteoarthritis, Knee in 30 participants. Completed in 10 July 2017.

Timeline

2 March 2017

Primary endpoint
10 July 2017

10 July 2017

Quick facts

Lead sponsor	Unity Biotechnology, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	30
Start date	2 March 2017
Primary completion	10 July 2017
Estimated completion	10 July 2017
Sites	1 location across United States

Drugs / interventions tested

Arthroscopy
Arthrocentesis
MRI — full drug profile →

Conditions studied

Osteoarthritis, Knee — all drugs for Osteoarthritis, Knee →

Sponsor

Unity Biotechnology, Inc. — full company profile →

Who can join

35 and older, any sex, with Osteoarthritis, Knee. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an exploratory non-drug, interventional biomarker study in approximately 30 eligible patients with active osteoarthritis to investigate the degree of senescence-associated disease. Patients will provide blood and urine and undergo MRI imaging with and without gadolinium enhancement. Following imaging, arthrocentesis of both knees and an arthroscopy of the target knee will occur to obtain fluid, synovium and cartilage for analysis.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases.
Walters HE, Cox LS. · · 2018 · cited 62× · PMID 30096787 · DOI 10.3390/ijms19082325
Senescence under appraisal: hopes and challenges revisited.
Davan-Wetton CSA, Pessolano E, Perretti M, Montero-Melendez T. · · 2021 · cited 41× · PMID 33439271 · DOI 10.1007/s00018-020-03746-x

Verify or expand the search:

Other trials of Arthroscopy

Trials testing the same drug.

NCT05807854 — RSA Vs RCR for Massive RCTs · NA · recruiting
NCT06747767 — Early Outcomes of Arthroscopic Versus Open Reduction for Developmental Dysplasia of the Hip in Children · NA · completed
NCT04758585 — Non-adherence to Pain Medication Increases Risk of Postoperative Frozen Shoulder · NA · completed

Other recruiting trials for Osteoarthritis, Knee

Currently open trials in the same condition.

NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT06488144 — Rehabilitation for Arthritis of The Knee: mainTaining Improvement for Veterans · Phase 3 · recruiting
NCT07386561 — Virtual Reality Therapy and Non-Sleep Deep Rest Relaxation After Joint Arthroplasty · NA · active not recruiting
NCT07514598 — Effect of J-Shaped Incision After Total Knee Arthroplasty (J-TKA) · NA · active not recruiting
NCT07058623 — Nurse-Led Telehealth vs In-Person Follow-Up After Total Knee Replacement · NA · recruiting

Other Unity Biotechnology, Inc. trials

Trials by the same sponsor.

NCT06011798 — Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE) · Phase 2 · completed
NCT05275205 — Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVIS · Phase 2 · completed
NCT04857996 — Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD) · Phase 2 · completed
NCT04537884 — Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Dege · Phase 1 · completed
NCT04349956 — Long-Term Follow-Up Study of Patients With Osteoarthritis of the Knee Treated With UBX0101 or Placebo · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03100799 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Unity Biotechnology, Inc.
Last refreshed: 1 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03100799.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing